Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.55 |
| ▸ | DPP4 | P27487 | 1/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.46 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8186292 | 1.00 | TSHR (0.56) | TSHRLMNALOXL2DPP4DPP7 | |
| SCHEMBL1176909 | 1.00 | TSHR (0.56) | TSHRLMNALOXL2DPP4DPP7 | |
| Hydrochloric Acid SCHEMBL4360113 | 0.98 | TSHR (0.55) | TSHRLMNALOXL2DPP4DPP7 | |
| SCHEMBL29254192 | 0.86 | LMNA (0.50) | TSHRLMNALOXL2DPP4DPP7 | |
| SCHEMBL514488 | 0.85 | LOXL2 (0.60) | TSHRLMNALOXL2DPP4DPP7 | |
| SCHEMBL5148823 | 0.85 | LOXL2 (0.60) | TSHRLMNALOXL2DPP4DPP7 | |
| SCHEMBL13014394 | 0.84 | TSHR (0.61) | TSHRLMNALOXL2IDO1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL9355954 | 0.84 | LOXL2 (0.58) | TSHRLMNALOXL2DPP4DPP7 | |
| SCHEMBL16093322 | 0.84 | LOXL2 (0.53) | TSHRLMNALOXL2DPP4DPP7 | |
| SCHEMBL16790561 | 0.84 | LOXL2 (0.53) | TSHRLMNALOXL2DPP4DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103275075-B | Zolmitriptan and preparation method thereof | CHENGDU TIANTAISHAN PHARMACEUTICAL CO LTD | 2015-01-07 | — | — | CN | claimed |
| CN-103275075-A | Zolmitriptan and preparation method thereof | CHENGDU TIANTAISHAN PHARMACEUTICAL CO LTD | 2013-09-04 | — | — | CN | claimed |
| CN-101693710-A | Method for preparing Zolmitriptan | SUZHOU LEADER CHEMICAL CO LTD | 2010-04-14 | — | — | CN | claimed |
| WO-2008018090-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF ZOLMITRIPTAN | MATRIX LABORATORIES LTD (IN) | 2008-02-14 | — | — | WO | claimed |
| US-20250049937-A1 | NOVEL AURISTATIN ANALOGS AND IMMUNOCONJUGATES THEREOF | ADCENTRX THERAPEUTICS INC (US) | 2025-02-13 | — | — | US | disclosed |
| EP-4453000-A1 | NOVEL AURISTATIN ANALOGS AND IMMUNOCONJUGATES THEREOF | Adcentrx Therapeutics Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| EP-3515896-B1 | CHIRAL CYCLEN COMPOUNDS AND THEIR USES | UNIV HONG KONG POLYTECHNIC (CN) | 2024-08-21 | — | — | EP | disclosed |
| CN-116574014-A | Preparation method of zolmitriptan intermediate | 山东锐顺药业有限公司 | 2023-08-11 | — | — | CN | disclosed |
| WO-2023122228-A1 | NOVEL AURISTATIN ANALOGS AND IMMUNOCONJUGATES THEREOF | ADCENTRX THERAPEUTICS INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023122228-A1 | NOVEL AURISTATIN ANALOGS AND IMMUNOCONJUGATES THEREOF | ADCENTRX THERAPEUTICS INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-11357873-B2 | Chiral cyclen compounds and their uses | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2022-06-14 | — | — | US | disclosed |
| US-20210283278-A1 | CHIRAL CYCLEN COMPOUNDS AND THEIR USES | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2021-09-16 | — | — | US | disclosed |
| EP-0636623-B1 | Indole derivatives as 5-HT1- like agonists | ASTRAZENECA AB (SE) | 2001-08-16 | — | — | EP | disclosed |
| EP-1092435-A1 | REMEDIES FOR DIABETES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000018770-A1 | PYRROLOPYRROLONE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXO GROUP LIMITED (GB) | 2000-04-06 | — | — | WO | disclosed |
| US-5863935-A | SYNTHESIS OF INDOLE DERIVATIVES OF HETEROCYCLIC COMPOUNDS FOR TREATMENT OF HEADACHES AND MIGRAINES | ZENECA LIMITED (GB) | 1999-01-26 | — | — | US | disclosed |
| EP-0486666-B1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | ZENECA LTD (GB) | 1997-08-13 | — | — | EP | disclosed |
| US-5466699-A | Indolyl compounds for treating migraine | BURROUGHS WELLCOME CO. (US) | 1995-11-14 | — | — | US | disclosed |
| US-5399574-A | 5-hydroxytryptamine agonists; vasoconstrictors | BURROUGHS WELLCOME CO. (US) | 1995-03-21 | — | — | US | disclosed |
| EP-0636623-A1 | Indole derivatives as 5-HT1- like agonists | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049937-A1 | NOVEL AURISTATIN ANALOGS AND IMMUNOCONJUGATES THEREOF | AURKC, AURKA, AURKB | TSHR 3325/4885LMNA 3626/4885LOXL2 4382/4885 |
| US-11357873-B2 | Chiral cyclen compounds and their uses | DCTN3, DCTN1, CDK3 | TSHR 845/4885LMNA 2197/4885LOXL2 4681/4885 |
| US-20210283278-A1 | CHIRAL CYCLEN COMPOUNDS AND THEIR USES | DCTN3, DCTN1, CDK3 | TSHR 845/4885LMNA 2197/4885LOXL2 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.